

Senzime secures large order on single use sensors from South Korea

Press release: Uppsala, September 15, 2020. Senzime AB (publ) today announces that the company has received another order from its distributor in South Korea. The order value amounts to approximately SEK 1 million and refers only to single use TetraSens sensors. The order will be processed during the current month.

This is the fourth major order placed by Senzime's distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 surgeries are performed annually where anesthesia and muscle relaxants are used.

" We have so far delivered 233 TetraGraph monitors to South Korea. This order shows the leverage in our business model. I expect more orders both for TetraGraph and disposable sensors from South Korea this year", says Pia Renaudin, Senzime CEO

TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to South Korea, Senzime has launched sales of TetraGraph in Japan, Australia, Europe and the United States.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 70-813 34 17, e-post: pia.renaudin@senzime.com

TO THE EDITORS

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on September 15, 2020, 09:45.